Head-To-Head Survey: Esperion Therapeutics (ESPR) vs. Its Competitors
Esperion Therapeutics (NASDAQ: ESPR) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Esperion Therapeutics to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk.
This table compares Esperion Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Esperion Therapeutics Competitors||-3,682.34%||-415.70%||-47.90%|
Valuation and Earnings
This table compares Esperion Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Esperion Therapeutics||N/A||-$131.29 million||-8.90|
|Esperion Therapeutics Competitors||$207.12 million||-$2.38 million||0.38|
Esperion Therapeutics’ competitors have higher revenue and earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
83.3% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 32.5% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Esperion Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Esperion Therapeutics Competitors||777||2915||6363||144||2.58|
Esperion Therapeutics currently has a consensus target price of $55.21, suggesting a potential upside of 7.35%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 8.81%. Given Esperion Therapeutics’ competitors higher probable upside, analysts clearly believe Esperion Therapeutics has less favorable growth aspects than its competitors.
Risk and Volatility
Esperion Therapeutics has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Esperion Therapeutics’ competitors have a beta of 1.67, indicating that their average stock price is 67% more volatile than the S&P 500.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.